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ABSTRACT: Introduction: In order to treat pain and psychomotor 
agitation, which are common symptoms in Neonatal Intensive 
Care Units (NICU), sedatives/opioid analgesics are used. 
However, its prolonged use, mainly in the continuous base, can 
provoke the Neonatal Abstinence Syndrome (NAS). Objectives: 
Evaluate the approach of NAS by opioids in newborns (NB) 
admitted in a NICU of Odete Valadares Maternity (OVM) in 
Belo Horizonte. Methods: Analysis of the medical records from 
the OVM pharmacy of the NB who have used methadone in 
between June 2013 to July 2014, additionally with diagnosis or 
risk of abstinence by opioids, confirmed clinically by the Finnegan 
scoring system. Results: All of the NB who have received 
methadone during the study time were evaluated. From the total 
of 17 NB, 6 were eliminated as they have been transferred to 
other services or evolved towards death, making it impossible 
to complete the data analysis. From 11 NB included, 7 were 
premature with gestational age under 28 weeks. There was a 
prevalence of the male gender (72,7%). All the infants received 
fentanyl continuously, which period of use was 37 days in average 
in the preterm NB, whereas being 25 days in the mature NB. The 
time spent to reach the control dose of methadone, meaning the 
sufficient dosage to avoid abstinence symptoms (Finnegan score 
< 8 in 3 consecutive evaluations) was in average 6 days and the 
time for drug suspension ranged from 10 to 159 days. From 11 NB, 
8 presented signs of abstinence after the beginning of methadone 
with the need of dose adjustment. Conclusion: The study allowed 
a preliminary evaluation of the NAS protocol along with the 
use of methadone in the service where it was held. There was a 
relation between the use of methadone and continuous sedation, 
which duration was prolonged in the NB of male gender and 
premature ones. Although a more detailed approach should be 
accomplished, considering the amount of ventilated NB in the 
period (256 NB), the number of NB with possible abstinence 
was relatively small (6,6%), which may mean a judicious use of 
opioids in this population.
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RESUMO: Introdução: Para tratar a dor e a agitação psicomotora, 
sintomas comuns em unidades de cuidados intensivos neonatais, 
são utilizados sedativos/analgésicos opióides. Contudo, seu uso 
prolongado, principalmente na forma contínua, pode provocar a 
Síndrome de Abstinência Neonatal (SAN). Objetivo: Avaliar a 
abordagem da Síndrome de Abstinência Neonatal por opióides 
em recém nascidos (RN) internados na unidade neonatal da 
Maternidade Odete Valadares em Belo Horizonte. Métodos: 
Análise dos prontuários de RN que usaram metadona no período 
de junho de 2013 a junho de 2014, a partir do levantamento feito 
na Farmácia da unidade, portanto com diagnóstico ou risco de 
abstinência por opióide, confirmada clinicamente pela escala 
de Finnegan. Resultados: Foram avaliados todos os RN que, 
no período de estudo, receberam metadona. Do total de 17 RN, 
6 foram eliminados pois receberam alta para outros serviços 
ou evoluíram para óbito, impossibilitando a análise completa 
dos dados. Dos 11 RN incluídos, 7 foram prematuros, com 
idade gestacional inferior a 28 semanas. Houve prevalência 
do sexo masculino (72,7%). Todos os RN receberam fentanil 
continuamente, cujo período de uso foi, em média, 37 dias nos 
RN prematuros e 25 dias nos RN a termo. O tempo gasto para que 
se atingisse a dose controle da metadona, ou seja, dose suficiente 
pata evitar os sintomas de abstinência (Escala de Finnegan <8 em 
3 avaliações consecutivas), em média, foi de 6 dias e o tempo 
para suspensão da mesma variou de 10 a 159 dias. Dos 11 RN 
acompanhados, 8 apresentaram sinais de abstinência após o início 
da metadona com necessidade de ajuste da mesma. Conclusão: 
O estudo permitiu uma avaliação preliminar do protocolo de 
abordagem da SAN e do uso da metadona no serviço em questão. 
Houve relação do uso da metadona com a sedação contínua, cuja 
duração foi prolongada nestes RN, com o gênero masculino e com 
a prematuridade. Considerando o número total de RN ventilados 
no período (256 RN), o número de RN com possível S.A.N 
foi relativamente pequeno (6.6%), podendo significar um uso 
criterioso de opióides nesta população, embora uma abordagem 
mais detalhada deva ser realizada.
Descritores: Síndrome de abstinência neonatal; Fentanila; 
Metadona; Recém-nascido.
INTRODUCTION
This study evaluated the protocol concerning the Neonatal Abstinence Syndrome (NAS) by 
opioids instituted in Odete Valadares Maternity (OVM), 
located in the city of Belo Horizonte, Minas Gerais state, 
in Brazil. This hospital provides comprehensive care to 
women’s health and their newborns (NB), performing 
approximately 400 deliveries per month. It is equipped 
with a Neonatal Intensive Care Unit (NICU) including 20 
hospital beds, accepting an average of 30 NB monthly. In 
June 2012 the standard operational procedure to the NAS 
approach was elaborated, since then the OVM has been 
having a positive outcome with the protocol implantation 
in the service.
The pain and psychomotor agitation are common 
disorders presented by the neonates hospitalized in 
NICU, especially the ones who have been submitted 
to surgical intervention or mechanical ventilation. The 
pharmacological therapy used to treat these clinical 
conditions includes anesthetics, sedatives and central and 
peripheral analgesic medicines.
In the NICU of OVM, the preferable drug to relieve 
these symptoms is fentanyl, taking into consideration its 
cost-effectiveness relation. It is a medication with great 
analgesic power, sedative and respiratory depression 
properties. When compared to morphine, standard 
drug in its category, fentanyl is 80 to 100 times more 
potent17, has a rapid onset of action and presents less 
hemodynamic impacts. It can be administered in continuous 
intravenous infusion orbolus. However, its prolonged use, 
predominantly in the uninterrupted scheme can lead to the 
Abstinence syndrome18, which is one of the most relevant 
complications of the extended treatment with opioids.
The risk of developing the NAS is proportional to 
the exposure time to opioids in intravenous administration4, 
beginning from the third day of medication. The clinical 
manifestations of NAS include hyperirritability of the 
central nervous system (CNS), respiratory, gastrointestinal 
and autonomic expressions14. The symptoms may vary and 
are common to other neonatal pathologies, what makes 
it difficult to be recognized, being often an exclusion 
diagnosis. There are scoring systems such as the Finnegan 
one15, (Chart 1) that assists in identifying and determining 
the NAS signs, being essential in the therapeutic approach 
to this clinical condition. The syndrome should be suspected 
when the NB, deprived of the drug amount that was being 
offered to them, start developing symptoms, which nature 
was described above, that cease with the adjustment of the 
drug in question.
The service strategies conducted to minimize the 
risk of NAS include the methadone prescription and the 
judicious use of continuous infusion of opioids, which 
should be restricted to special occasions, when the agitation 
and stress of the NB impose a greater risk to their recovery 
and jeopardize ventilatory assistance. The vast majority 
of ventilated and post surgery infants, were successfully 
treated with bolus opiates. The gradual weaning and the use 
of methadone are other measures described in the protocol 
to prevent the NAS.
Therefore, considering the pain approach as an 
increasingly adopted measure by the multidisciplinary 
teams engaged in neonatal care, the NAS should demand 
the same concern pertaining to its adequately prevention 
and treatment, and it must receive the same consideration 
given to the pain protocols in the NICU.
In order to treat the NAS there is a wide variety 
of pharmacological and nonpharmacological therapies, 
adopted accordingly to the protocols of each institution. 
In OVM, the drug of choice is methadone, supported by 
international literature as first line therapy for NAS1,5, which 
can be justified as it is a potent opiate with a prolonged 
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half-life (26 hours)13, being this feature important when 
considering the drug removal as it allows the gradual raising 
of intervals in between administration what eases the drug 
withdraw. The nonpharmacological treatment has shown to 
be supportive and an addition to the treatment.
The NAS protocol of OVM defines (Flowchart 1) 
the therapeutic conduct to be followed in NB with diagnosis 
Chart 1. FinneganScoring System
Symptoms Points Symptoms Points Symptons Points
Excessive high pitched (or 
other) cry (< 5 min) 2
Moderate-severe tremors when 
undisturbed 4
Frequentsneezing (> 3-4/
interval) 1
Continuous high pitched (or 
other) cry (> 5 min) 3 Increasedmuscletone 1 Nasal flaring 2
Sleep< 1 hour afterfeeding 3 Excoriation (eg. Chin, knees, elbows, toes, nose) 1 Respiratory rate > 60/min 1
Sleep< 2 hours afterfeeding 2 Myclonic jerks (twitching/jerking of limbs) 3
Respiratory rate > 60/min with 
retractions 2
Sleep< 3 hours afterfeeding 1 Generalizedconvulsions 5 Excessivesucking 1
Hyperactive Moro reflex 2 Sweating 1 Poor feeding (infrequent/uncoordinated suck) 2
Moderatelyhyperactive Moro 
reflex 3 Hyperthermia (37.2 – 38.2°C) 1
Regurgitation (≥ 2 times 
during/past feed) 2
Mildtremorswhendisturbed 1 Hyperthermia (≥ 38.4°C) 2 Projectilevomiting 3
Moderate-severe tremors 
when disturbed 2 Molting 1 Loosestool 2
Mildtremorswhenundisturbed 3 Nasal stuffiness 1 Waterystool 3
Flowchart 1. Flowchart of management of the neonatal abstinence syndrome
Legend: * Maximum dose of fentanyl in mcgr/hr multiplied by 60. The result is multiplied by 2. This last result refers to the Methadone 
dose in mg to be administered every 12 hours initially4 
**Dose capable of leaving the NB without abstinence signs and symptoms (Finnegan Score less than 8 in 3 consecutive evaluations).
74
Ferreira CCR, et al. Evaluation of the protocol regarding the Neonatal Abstinence Syndrome by opioids.
or high clinical suspicion of NAS, as described below. 
The NB who have used opioids continuously for a 
period < 3 days: the use should be interrupted abruptly. For 
the NB who have used opioid continuously from 3 to 7 days: 
the dose of the venous opioid should be reduced in 25 to 
30 % per day and the suspension may occur according to 
tolerance in 72 hours, when it is essential to keep observing 
for possible signs of abstinence. For the NB who have 
used opioids for more than 7 days: convert the maximum 
dose of fentanyl infused to methadone and administer 
it every 12 hours. Perform the Finnegan scoring system 
every 12 hours until the control dose is reached (the one 
able of leaving the NB without abstinence manifestations 
- Finnegan score < 8 in 3 consecutive evaluations). Once 
the control dose has been achieved, prescribe it every 24 
hours and start reducing 0.05 mg/kg/day, according to 
tolerance, until its removal. For the NB with suspicion 
of abstinence who are no longer under opioids: confirm 
the suspicion of NAS by the Finnegan scoring system, 
initiate methadone at the empirical dose of 0,05 to 0,1 
mg/kg every 6 hours, what may be increased in 0,05 mg/
kg until the symptoms control16. Once the control dose 
has been reached, the methadone interval should be raised 
until its administration is performed every 24 hours, when 
the reduction of 0.05 mg/kg/day can begin, according to 
tolerance, until its withdraw.
OBJECTIVES
The present study has as an objective to evaluate the 
protocol regarding the approach of the NAS by opioids in 
NB who were hospitalized in the NIUC/OVM, by means 
of identification and study of the NB who have used 
methadone in the period of June 2013 to July 2014. 
MATERIALS AND METHODS
This study was based on a retrospective research 
conducted between the period of June 2013 to July 2014.
The inclusion criteria were: NB admitted in the NICU/
OVM who were prescribed methadone and have been 
discharged from this medical service until the end of 
June 2014. The research excluded all NB who have been 
dismissed to another service or that evolved towards death, 
in that one year and one month time course. To execute 
the study, it was analyzed the medical records from the 
NB who achieved the inclusion principle, by the raising 
made in the OVM pharmacy. The control of methadone 
use was accurately recorded beginning in June 2013. It was 
collected the following data: NB identification , medical 
record number, birth date, gestational age, weight from 
the NB birth, gender, total time of opioid use, maximum 
dosage administered, time necessary in order to reach 
the methadone control dose, signs observed before and 
after the beginning of methadone, interval spent until the 
methadone suspension, opioid indication, total duration 
of mechanical ventilation (MV), if the NB was still under 
MV when beginning the methadone, besides the main 
diagnostics of these NB.
RESULTS/DISCUSSION
The risk of developing the NAS by opioids is 
proportional to the exposure time to these drugs in venous 
administration1. The Finnegan Scoring System15 (Chart 2) is 
the tool used in the institution, and supported by literature, 
to guide with the diagnostic and in monitoring infants with 
the suspicion of this affection. It should be performed 
every 8 hours15. This method keeps score considering 
four different systems already described above, which 
are included in the clinical manifestations of the NAS. 
Abstinence is considered when the score is higher than 8 
in 3 consecutive evaluations, if there is not another better 
clinical explanation to justify the symptoms, and if these 
ones disappear immediately after restarting or raising drug 
amount15.
The NAS protocol of OVM aims to define the 
therapeutic conduct to be followed in NB with diagnosis 
or high clinical suspicion of the syndrome, being fentanyl 
(FNT), the most used opioid in OVM and the most indicated 
one due to its pharmacological properties1.
The diagnostic suspicion is raised by the presence 
of abstinence signs in NB who have used opioids for more 
than 7 days. 
The strategies used in NICU/OVM to minimize the 
risk of NAS include the judicious use of continuous infusion 
of opioids, which are restricted to certain instances, when 
the NB agitation and stress impose risk to their recovery 
and jeopardize the ventilatory assistance. The majority 
of the NB who are ventilated or post-surgery are treated 
successfully with bolus opioids. The gradual weaning of 
opioids and the use of methadone are essential measures 
to the NB who used the continuous scheme.
In this work all of the NB who were using 
methadone in the study period were evaluated:
From the total of 17 NB, 6 were disqualified since 
they have either been dismissed from the service or have 
evolved towards death, making it impossible to analyze the 
data entirely. From 11 NB included, 7 were premature with 
gestational age under 28 weeks and there was a prevalence 
of male gender (72.7%). The birth weight varied between 
470 grams to 3920 grams. According to Jansson et al.7 
the male gender and prematurity are characteristics that 
make the NB vulnerable to the NAS by opioids. Every NB 
received fentanyl continuously and the period of use was 
in average 37 days in the premature NB, and 25 days in the 
mature ones. The fentanyl dosage ranged between 2 to 7 
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mcgr/kg/hour. Six NB were been submitted to mechanical 
ventilation when they initiated the methadone. The time 
spent to reach the control dose was in general 6 days and 
the time for drug suspension varied between 10 to 159 
days. From the 11NB, 8 presented signs of abstinence 
once the methadone was introduced, with the need of 
dose adjustment. From the total of 256 NB who have been 
ventilated in the period of the study in OVM, only 6.6% of 
them showed a probability of abstinence.
The main signs of abstinence noticed in the study 
were: agitation, tremors, excessive high pitched crying, 
drop in oxygen saturation, tachypnea, hypertonicity of 
the members and photo reactive pupils. These symptoms 
concur with the ones described in the reference literature15. 
It was not possible to establish a connection between the 
previous pathologies and the methadone need, however, 
there was a relation including prolonged MV, which 
comprehended 100% of the cases studied.
CONCLUSION
This study allowed a preliminary evaluation of 
the protocol regarding the NAS approach and the use of 
methadone in our medical service. It was observed that 
the male gender and premature NB suffered more from 
the severity of the symptoms and spent an extended period 
conductive to the drug suspension.
Considering the number of 256 NB under MV in the 
study period, the 6.6% prevalence of abstinence probability 
was relatively small, meaning a judicious use of opioids 
in that population.
What is expected for the future of the NAS is that 
this syndrome receives the same attention that is given 
to the pain approach, for the reason that it is a situation 
that interferes negatively in the evolution of any clinical 
condition.
Due to the relevance of the syndrome, it should 
be the theme of further studies, in the interest of creating 
guidelines to standardize its prevention and treatment in 
every medical institute.
In the current study it was analyzed the implantation 
of the NAS protocol in OVM. The scientific committee has 
initiated another study within the unit, with the purpose of 
comparing the incidence of NAS in those NB who have 
used fentanyl continuously and the ones that were treated 
with the bolus method.
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